Immunovant (IMVT) Assets (2018 - 2026)
Immunovant's (IMVT) quarterly Assets came in at $957.0 million in Q1 2026, up 23.29% YoY from $776.2 million in Q1 2025, and down 9.06% on a QoQ basis from $1.1 billion in Q4 2025.
Immunovant (IMVT) Assets (2018 - 2026) Analysis & Trends
Immunovant (IMVT) has 9 years of Assets data on file, last reported at $957.0 million in Q1 2026.
- Quarterly Assets rose 23.29% year-over-year to $957.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $957.0 million (up 23.29% YoY) and the FY2026 annual result came in at $957.0 million, up 23.29% from the prior year.
- Assets eased to $957.0 million in Q1 2026, from $1.1 billion in the prior quarter.
- In the past five years, Assets ranged from a high of $1.1 billion in Q4 2025 to a low of $292.1 million in Q3 2023.
- A 5-year average of $578.9 million and a median of $515.7 million in 2024 frame the typical range for Assets.
- Annual changes were most pronounced in 2024 — Assets tumbled 40.83% — and 2025, when it soared 150.01%.
- Tracing IMVT's Assets over 5 years: stood at $456.2 million in 2022, then soared by 55.94% to $711.4 million in 2023, then plunged by 40.83% to $420.9 million in 2024, then soared by 150.01% to $1.1 billion in 2025, then declined by 9.06% to $957.0 million in 2026.
- The last three Assets figures came in at $957.0 million (Q1 2026), $1.1 billion (Q4 2025), and $583.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Immunovant | 8.63 Bn | 7.83 Bn | - | 852.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 852.49 Mn |
| Mar 31, 2026 | 957.01 Mn |
| Dec 31, 2025 | 1.05 Bn |
| Sep 30, 2025 | 582.96 Mn |
| Jun 30, 2025 | 661.44 Mn |
| Mar 31, 2025 | 776.22 Mn |
| Dec 31, 2024 | 420.93 Mn |
| Sep 30, 2024 | 515.71 Mn |
| Jun 30, 2024 | 589.68 Mn |
| Mar 31, 2024 | 666.37 Mn |
| Dec 31, 2023 | 711.45 Mn |
| Sep 30, 2023 | 292.07 Mn |
| Jun 30, 2023 | 351.22 Mn |
| Mar 31, 2023 | 405.84 Mn |
| Dec 31, 2022 | 456.24 Mn |
| Sep 30, 2022 | 428.15 Mn |
| Jun 30, 2022 | 458.66 Mn |
| Mar 31, 2022 | 515.56 Mn |
| Dec 31, 2021 | 543.18 Mn |
| Sep 30, 2021 | 566.73 Mn |